# DESCRIPTION

- claim benefit of provisional application

## FIELD OF THE INVENTION

- disclose method and compositions for treating solid tumor cancer

## BACKGROUND OF THE INVENTION

- introduce ovarian cancer statistics
- describe current treatment options
- motivate need for new approaches
- introduce histone deacetylases and HDAC inhibitors
- describe HDAC inhibitor classes
- discuss HDAC inhibitor effects on gene expression
- introduce nuclear factor-kappa B and IκB kinase
- describe NF-κB activation and regulation
- discuss NF-κB role in cancer
- motivate IKK inhibitors for cancer treatment

## SUMMARY OF THE INVENTION

- disclose method for treating solid tumor cancer
- disclose method for determining susceptibility to combination therapy

## DETAILED DESCRIPTION OF THE INVENTION

### I. Methods of Use

- introduce method for treating solid tumor cancer
- specify HDAC inhibitor and IKK inhibitor
- list examples of HDAC inhibitors
- list examples of IKK inhibitors
- specify embodiment of HDAC inhibitor and IKK inhibitor
- list examples of solid tumors
- specify embodiment of solid tumor cancer
- define drug-resistant solid tumor
- specify embodiment of drug-resistance
- define subject in need thereof
- specify embodiment of subject
- specify administration of HDAC inhibitor and IKK inhibitor
- define in combination with
- define concomitant administration
- define therapeutically effective amount
- specify embodiment of therapeutically effective amount
- specify route of administration
- specify form of HDAC inhibitor and IKK inhibitor
- specify dosage of HDAC inhibitor
- specify embodiment of dosage
- specify administration schedule
- specify embodiment of administration schedule
- specify intravenous administration
- specify embodiment of intravenous administration
- specify dosing cycle
- describe HDAC inhibitor administration
- specify dosage and frequency of HDAC inhibitor
- describe IKK inhibitor administration
- specify dosage and frequency of IKK inhibitor
- describe intravenous administration of IKK inhibitor
- specify dosage and frequency of intravenous IKK inhibitor
- describe oral administration of IKK inhibitor
- specify dosage and frequency of oral IKK inhibitor
- describe combination therapy of HDAC and IKK inhibitors
- specify administration routes of HDAC and IKK inhibitors
- describe sequential administration of HDAC and IKK inhibitors
- describe concomitant administration of HDAC and IKK inhibitors
- associate IL-8 with ovarian cancer progression
- describe HDAC inhibitor-induced IL-8 production
- describe IKK inhibitor suppression of HDAC-induced IL-8 production
- describe combination therapy effectiveness in reducing tumor growth
- introduce method for determining cancer susceptibility to combination therapy
- isolate cancer or neoplastic cells or cell lines
- treat cells with combination therapy
- assess effect of treatment on IL-8 production and cell survival
- describe cells used in method
- describe isolating cancer or neoplastic cells or cell lines
- treat cells with HDAC and IKK inhibitors
- assess effect of treatment on IL-8 production and cell survival
- describe determining therapeutically effective amount of combination therapy
- compare combination therapy to HDAC inhibitor alone

### II. Pharmaceutical Compositions

- define pharmaceutical composition
- describe HDAC and IKK inhibitors
- specify administration route
- describe pharmaceutically acceptable carrier
- list carrier characteristics
- describe enteral administration
- describe parenteral administration
- specify solid and liquid dosage forms
- describe dosing intervals
- describe administration methods
- specify intravenous injection
- describe oral delivery
- describe liquid gel capsule
- describe solid dosage form
- list pharmaceutical composition references
- describe coating materials
- list optional excipients
- describe diluents
- describe binders
- describe lubricants
- describe disintegrants
- describe stabilizers
- describe surfactants
- describe modified release

### III. Kit

- define kit
- describe HDAC and IKK inhibitors
- specify oral or intravenous delivery
- describe solid dosage form
- describe liquid dosage form
- specify kit for solid tumor cancers
- describe container
- describe label or package insert
- describe directions for administration
- describe kit variations

## EXAMPLES

- introduce nonlimiting examples

### Example 1: HDAC Inhibitors Increase IL-8 Expression in Ovarian Cancer Cells

- describe methods
- describe results
- analyze data
- discuss significance
- conclude HDAC inhibition-induced IL-8 release

### Example 2: HDAC Inhibitors Increase IL-8 Expression in Cervical Cancer Cells

- describe methods
- describe results

### Example 3: IKK Inhibitors Suppress the HDAC Inhibition-Induced IL-8 Expression in Ovarian Cancer Cells

- describe methods
- describe results
- analyze data

### Example 4: Combination of HDAC Inhibitor and IKK Inhibitor Enhances the HDAC Inhibitor Effectiveness in Reducing Solid Tumor Growth in Vivo

- describe methods
- describe results
- analyze data
- discuss significance
- conclude combination therapy effectiveness

